Trial Profile
A 24-month Multicenter, Open-label Phase II Trial Investigating the Safety and Efficacy of Repeated velmanase alfa (recombinant human alpha-mannosidase) Treatment in Pediatric Patients below 6 years of age with Alpha-Mannosidosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2023
Price :
$35
*
At a glance
- Drugs Velmanase alfa (Primary)
- Indications Alpha-Mannosidosis
- Focus Adverse reactions; Pharmacodynamics
- Acronyms rhLaman-08
- Sponsors Chiesi Farmaceutici
- 01 Jul 2023 Results for long-term safety and efficacy , published in the Journal of Inherited Metabolic Disease
- 20 Jul 2020 Status changed from active, no longer recruiting to completed.
- 05 Mar 2019 Status changed from recruiting to active, no longer recruiting.